Cabaletta Bio (CABA) Financials

Cabaletta Bio Inc (CABA) is a biotechnology company that is focused on the development of engineered T cell therapies for the treatment of B cell-mediated autoimmune diseases. The company's therapies are designed to selectively eliminate B cells that produce disease-causing autoantibodies, while preserving the beneficial aspects of the immune system. Cabaletta Bio's lead product candidate, DSG3-CAART, is being developed for the treatment of mucosal pemphigus vulgaris (mPV), a rare autoimmune blistering disorder that affects the mucous membranes.

In terms of financials, Cabaletta Bio Inc reported total revenue of $5.2 million for the year ended December 31, 2020. The company's gross profit for the same period was $3.8 million. Cabaletta Bio's operating cash flow was -$51.5 million, while its financing cash flow was $273.4 million. The company's free cash flow for the year was -$46.3 million. Cabaletta Bio had cash equivalents of $301.6 million as of December 31, 2020, and total assets of $312.8 million. The company's total liabilities were $35.6 million, and its stockholders' equity was $275.7 million.